Screened
(N=160)

Discontinued during 8-week treatment period (N=20, 12.6%)
Reasons:
- Adverse event N=6
- Patient decision N=4
- Lack of efficacy N=2
- Parent/caregiver decision N=2
- Protocol violation N=2
- Physician decision N=2
- Meeting exclusion criterion N=1
- Preexisting condition N=1

Enrolled and entered in study
(N=159, 100%)

Completed 8-week treatment period
(N=139, 87.4%)

Completed treatment period, not continued into extension period
(N=2, 1.3%)

Discontinued during extension period (N=26, 16.4%)
Reasons:
- Lack of efficacy N=8
- Protocol violation N=7
- Parent/caregiver decision N=4
- Patient decision N=4
- Lost to follow up N=2
- Adverse event N=1

Continued treatment into extension period
(N=137, 86.2%)

Completed treatment at week 24
(N=111, 69.8%)